Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases

NCT00337155 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00337155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
December 31, 2009
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, prostate cancer